Virtual Reality and Psychedelic Synergy

Study finds that these altered states are quite similiar.


In the psychedelic sixties, Timothy Leary chanted “Turn on, Tune in, Dropout”. By the end of the twentieth century, however, Leary adjusted his well-known catchphrase to changing times and evolving technology: “Turn On, Boot Up, Jack In,”1 he said, arguing that cyberdelics—the union of cyberculture with psychedelic substances—had the capacity to birth a new paradigm. Similarly, psychedelic spearhead Terence McKenna aptly said that the psychedelic substances of the future would be more like computers, and the computers of the future would be more like psychedelics. 

Both luminaries foreshadowed a future where psychedelics and technology would merge, birthing a novel modality and new terrains to be explored. It seems as if that time has come, with new research highlighting the many similarities between psychedelic experiences and Virtual Reality (VR) and detailing the potential therapeutic and recreational implications. 

In a recent article entitled “Psychedelics and Virtual Reality: Parallels and Applications,” published in Therapeutic Advances in Psychopharmacology, Aday, Davoli and Bloesch offer a comprehensive literature review of the topic, and speculate on a future where psychedelics and technology are one.2 

Altered States and Awe-Inducing Experiences

As the study notes, psychedelic experiences and virtual reality have the common ability to alter perceptual experience, particularly visual processing. DMT is an emblematic example. As demonstrated by Alamina, et. al., participants in their study with eyes closed and under the influence of DMT showed patterns in cortical electroencephalogram (EEG) remarkably similar to those of controls with eyes open.3 Individuals undergoing a psychedelic experience having similar EEGs to controls at baseline speaks to DMT’s ability to “replace ongoing mental experience” as DMT researcher Rick Strassman says.4

This capacity to immerse the user in a hallucinatory landscape is similar to VR technology, in which users find themselves immersed in a wholly artificial environment. The qualitative experience of transcending limitations proposed by the physical body and consensus reality is often expressed.5 A common motivation for using DMT is a general curiosity of and a desire to explore visual phenomena6, which may likewise be true for VR enthusiasts. 

Immersive doses of psychedelics and VR possess the mutual capacity to evoke awe, an emotion equal parts fear and reverence. This may be beneficial in therapeutic contexts. Experiences of awe reported in psychedelic states have been positively correlated with a sense of heightened curiosity, improvements in mental health, and enhanced performance in school or at work.7,8 Similarly, VR is a reliable tool in facilitating emotionally significant experiences. Chirico, Ferrise, Cordella, et al. found that exposure to awe-inducing virtual environments was associated with increased well-being and a perceived sense of “vastness and connectedness.”9 These outcomes are strikingly similar to the emotional and personal effects reported after psychedelic experiences. 

Mapping Uncharted Territory

Research into psychedelic science has accelerated steadily, particularly since 2018 when psilocybin was granted breakthrough therapy status by the FDA as a potential remedy for Treatment-Resistant Depression (TRD).10 As this body of work is elaborated upon, VR may prove beneficial as an adjunct to the new psychedelic-assisted therapies currently in their infancy. A vast body of literature has accumulated using psychedelics to treat various ailments including depression,11 anxiety,12 end-of-life distress,13 and substance misuse.14 Evidence consistently suggests that these substances can facilitate remission in a vast array of afflictions.

While it has become increasingly established that psychedelics confer obvious benefits, how this happens exactly and how their actions are mediated is not fully understood. With the onslaught of modern literature, ideas ranging from the content of mystical experiences15 and that of ego dissolution16 have been proposed, in addition to mechanistic explanations like neurogenesis17 and changes in neural plasticity.18 Recently, a hampering in the activity of the brain’s default mode network has become a popular framework. 

In addition to improving our understanding of psychedelics with regards to basic science, VR may have many purely therapeutic benefits of its own. VR has been studied as a potential treatment for many of the same ailments as psychedelics, a unique opportunity to survey the effects of utilizing both in tandem. Like psychedelics, VR has been proposed as a remedy for anxiety,21 depression,22 and substance misuse,23 among other disorders. It has also been used in bed-ridden individuals to simulate travel, illustrating that VR and psychedelics together may be especially helpful in the palliative care of the sick and those at the end of life.24

Virtual environments also provide immersive settings in which individuals can confront fears and/or facilitate memory reconsolidation of events or prospects that may frighten them, aiding in the construction of new associations and alternate perceptions.25 Subjective ratings of “presence” and “immersion” in virtual settings correlate with many positive outcomes when used alongside psychotherapy, suggesting that transcending one’s typical perspective is important in VR’s therapeutic efficacy.26 This presents yet another unique opportunity to study its use alongside psychedelics. 


Long after Leary and McKenna’s speculations, Aday, Davoli, and Bloesch’s research echoes a similar sentiment, but in a more modern and nuanced sense. This comprehensive review reiterates the potential of using VR technology as an adjunct to psychedelic therapies. This synergy could have far-reaching implications, both in the therapeutic and recreational use of psychedelics. VR used in tandem with psychedelic substances may be an entirely new direction for psychedelic research, medicine, and for the study of consciousness generally. 

Christopher is a recent biology graduate from Wayne State University. His research interests include neuropharmacology and the basic sciences as they relate to elucidating the mechanisms and therapeutic potential of psychedelics.


Notify of

Inline Feedbacks
View all comments
  1. Leary T. Chaos and Cyber Culture. 20th ed. Ronin Publishing; 2014.
  2. Aday JS, Davoli CC, Bloesch EK. Psychedelics and virtual reality: parallels and applications. Therapeutic Advances in Psychopharmacology. 2020; 10:204512532094835. doi:10.1177/2045125320948356
  3. Alamia A, Timmermann C, Nutt DJ, VanRullen R, Carhart-Harris RL. DMT alters cortical travelling waves. van Wassenhove V, Behrens TE, Alexander DM, eds. eLife. 2020;9: e59784. doi:10.7554/eLife.59784
  4. Strassman RJ. Human psychopharmacology of N, N-dimethyltryptamine. Behavioural Brain Research. 1995;73(1-2):121-124. doi:10.1016/0166-4328(96)00081-2
  5. Guttentag DA. Virtual reality: Applications and implications for tourism. Tourism Management. 2010;31(5):637-651. doi:10.1016/j.tourman.2009.07.003
  6. Metzner R. The Ayahuasca Experience: A Sourcebook on the Sacred Vine of Spirits. Park Street Press; 2014.
  7. Anderson CL, Dixson DD, Monroy M, Keltner D. Are awe‐prone people more curious? The relationship between dispositional awe, curiosity, and academic outcomes. Journal of Personality. Published online December 10, 2019. doi:10.1111/jopy.12524
  8. Rudd M, Vohs KD, Aaker J. Awe Expands People’s Perception of Time, Alters Decision Making, and Enhances Well-Being. Psychological Science. 2012;23(10):1130-1136. doi:10.1177/0956797612438731
  9. Chirico A, Ferrise F, Cordella L, Gaggioli A. Designing Awe in Virtual Reality: An Experimental Study. Frontiers in Psychology. 2018;8. doi:10.3389/fpsyg.2017.02351
  10. Aday JS, Bloesch EK, Davoli CC. Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20th Century. Journal of Psychoactive Drugs. Published online March 6, 2019:1-8. doi:10.1080/02791072.2019.1581961
  11. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2017;235(2):399-408. doi:10.1007/s00213-017-4771-x
  12. Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology. 2014;29(1):57-68. doi:10.1177/0269881114555249
  13. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology. 2016;30(12):1165-1180. doi:10.1177/0269881116675512
  14. Nunes AA, dos Santos RG, Osório FL, Sanches RF, Crippa JAS, Hallak JEC. Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. Journal of Psychoactive Drugs. 2016;48(3):195-205. doi:10.1080/02791072.2016.1188225
  15. Russ SL, Carhart-Harris RL, Maruyama G, Elliott MS. Replication and extension of a model predicting response to psilocybin. Psychopharmacology. 2019;236(11):3221-3230. doi:10.1007/s00213-019-05279-z
  16. Letheby C, Gerrans P. Self unbound: ego dissolution in psychedelic experience. Neuroscience of Consciousness. 2017;2017(1). doi:10.1093/nc/nix016
  17. Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN. A Single Dose of 5-MeO-DMT Stimulates Cell Proliferation, Neuronal Survivability, Morphological and Functional Changes in Adult Mice Ventral Dentate Gyrus. Frontiers in Molecular Neuroscience. 2018;11. doi:10.3389/fnmol.2018.00312
  18. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
  19. S M, M A, C J. Classical Psychedelics for the Treatment of Depression and Anxiety: A Systematic Review. Journal of affective disorders. Published November 1, 2019.
  20. Aday JS, Bloesch EK, Davoli CC. Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect? Journal of Cognitive Enhancement. 2019;4(2):219-227. doi:10.1007/s41465-019-00151-6
  21. Powers MB, Emmelkamp PMG. Virtual reality exposure therapy for anxiety disorders: A meta-analysis. Journal of Anxiety Disorders. 2008;22(3):561-569. doi:10.1016/j.janxdis.2007.04.006
  22. Falconer CJ, Rovira A, King JA, et al. Embodying self-compassion within virtual reality and its effects on patients with depression. BJPsych Open. 2016;2(1):74-80. doi:10.1192/bjpo.bp.115.002147
  23. Metcalf M, Rossie K, Stokes K, Tallman C, Tanner B. Virtual Reality Cue Refusal Video Game for Alcohol and Cigarette Recovery Support: Summative Study. JMIR Serious Games. 2018;6(2):e7. doi:10.2196/games.9231
  24. Niki K, Okamoto Y, Maeda I, et al. A Novel Palliative Care Approach Using Virtual Reality for Improving Various Symptoms of Terminal Cancer Patients: A Preliminary Prospective, Multicenter Study. Journal of Palliative Medicine. 2019;22(6):702-707. doi:10.1089/jpm.2018.0527
  25. Wilhelm FH, Pfaltz MC, Gross JJ, Mauss IB, Kim SI, Wiederhold BK. Mechanisms of Virtual Reality Exposure Therapy: The Role of the Behavioral Activation and Behavioral Inhibition Systems. Applied Psychophysiology and Biofeedback. 2005;30(3):271-284. doi:10.1007/s10484-005-6383-1
  26. Mitrousia V, Giotakos O. Virtual reality therapy in anxiety disorders. Psychiatriki. 2016;27(4):276-286. doi:10.22365/jpsych.2016.274.27